|
|
||||||||
Departments of 1Medicine and 2Pharmacology, University of California, San Diego, La Jolla, California 92093-0618
Submitted 20 March 2003 ; accepted in final form 3 September 2003
In many types of heart failure cardiac myocyte Ca2+ handling is abnormal because of downregulation of key Ca2+-handling proteins like sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)2a and ryanodine receptor (RyR)2. The alteration in SERCA2a and RyR2 expression results in altered cytosolic Ca2+ transients, leading to abnormal contraction. Sorcin is an EF-hand protein that confers the property of caffeine-activated intracellular Ca2+ release in nonmuscle cells by interacting with RyR2. To determine whether sorcin could improve the contractile function of the heart, we overexpressed sorcin in the heart of either normal or diabetic mice and in adult rat cardiomyocytes with an adenoviral gene transfer approach. Sorcin overexpression was associated with an increase in cardiac contractility of the normal heart and dramatically rescued the abnormal contractile function of the diabetic heart. These effects could be attributed to an improvement of the Ca2+ transients found in the cardiomyocyte after sorcin overexpression. Viral vector-mediated delivery of sorcin to cardiac myocytes is beneficial, resulting in improved contractile function in diabetic cardiomyopathy.
calcium handling; gene therapy
This article has been cited by other articles:
![]() |
J. Suarez, B. Scott, and W. H. Dillmann Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1439 - R1445. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. H. Talukder, A. Kalyanasundaram, L. Zuo, M. Velayutham, Y. Nishijima, M. Periasamy, and J. L. Zweier Is reduced SERCA2a expression detrimental or beneficial to postischemic cardiac function and injury? Evidence from heterozygous SERCA2a knockout mice Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1426 - H1434. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Belke, E. Swanson, J. Suarez, B. T. Scott, A. E. Stenbit, and W. H. Dillmann Increased expression of SERCA in the hearts of transgenic mice results in increased oxidation of glucose Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1755 - H1763. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. An and B. Rodrigues Role of changes in cardiac metabolism in development of diabetic cardiomyopathy Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1489 - H1506. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hu, D. Belke, J. Suarez, E. Swanson, R. Clark, M. Hoshijima, and W. H. Dillmann Adenovirus-Mediated Overexpression of O-GlcNAcase Improves Contractile Function in the Diabetic Heart Circ. Res., May 13, 2005; 96(9): 1006 - 1013. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wellner, R. Dechend, J.-K. Park, E. Shagdarsuren, N. Al-Saadi, T. Kirsch, P. Gratze, W. Schneider, S. Meiners, A. Fiebeler, et al. Cardiac gene expression profile in rats with terminal heart failure and cachexia Physiol Genomics, February 10, 2005; 20(3): 256 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Suarez, B. Gloss, D. D. Belke, Y. Hu, B. Scott, T. Dieterle, Y.-K. Kim, M. L. Valencik, J. A. McDonald, and W. H. Dillmann Doxycycline inducible expression of SERCA2a improves calcium handling and reverts cardiac dysfunction in pressure overload-induced cardiac hypertrophy Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2164 - H2172. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |